All News
TNF inhibitors and radiographic progression in axSpA
A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axSpA, whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.
Read ArticleTelemedicine Upside Interview with Dr. Alvin Wells
In spite of the transformative growth of telemedicine during the COVID-19 pandemic, rheumatologists use of telemedicine is waning, much like the use of masks. Dr. Jack Cush interviews telemedicine guru, Dr. Alvin Wells, on the current state of telemedicine and what the future holds for telehealth in rheumatology.
Read ArticleRheumatoid Arthritis, Dementia and Cognitive Dysfunction
Rheumatoid arthritis (RA) has been linked to a higher risk of dementia and cognitive dysfunction, but interestingly this association has diminished in the last few decades with aggressive DMARD and targeted therapies..
Read ArticleMethotrexate and hepatic fibrosis: we must be doing something right
Methotrexate may be a rheumatologist’s best friend, but a key part of counselling any patient about its use has always been the risk of hepatotoxicity.
Read ArticleNew Insights into Uveitis in Spondyloarthritis
Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis.
Read Article
Links:

Links:

Links:

Links:

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:

Links:

Links:

Links:

Links:

Links:

Links:

Links:

Links:

Links: